EA200000596A1 - Tat вич-1 или его производные для профилактической и лечебной вакцинации - Google Patents

Tat вич-1 или его производные для профилактической и лечебной вакцинации

Info

Publication number
EA200000596A1
EA200000596A1 EA200000596A EA200000596A EA200000596A1 EA 200000596 A1 EA200000596 A1 EA 200000596A1 EA 200000596 A EA200000596 A EA 200000596A EA 200000596 A EA200000596 A EA 200000596A EA 200000596 A1 EA200000596 A1 EA 200000596A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tat
nef
gag
rev
hiv
Prior art date
Application number
EA200000596A
Other languages
English (en)
Other versions
EA004330B1 (ru
Inventor
Барбара Энсоли
Original Assignee
Иституто Супериоре Ди Санита'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иституто Супериоре Ди Санита' filed Critical Иституто Супериоре Ди Санита'
Publication of EA200000596A1 publication Critical patent/EA200000596A1/ru
Publication of EA004330B1 publication Critical patent/EA004330B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

(57) Настоящее изобретение относится к Tat как активной основе профилактической и/или лечебной вакцины против ВИЧ-инфекции, развития ее до СПИДа и развития опухолей и других синдромов и симптомов у субъектов, инфицированных ВИЧ. Tat находится в биологически активной форме, или в виде рекомбинантного белка или пептида, или в виде ДНК. Конкретнее, изобретение относится к вакцине на основе Tat ВИЧ-1 в качестве иммуногена, инокулируемого в виде ДНК и/или рекомбинантного белка или пептидов, одних или в сочетании с другими генами или вирусными генными продуктами (Nef, Rev, Gag) или их частями, или в сочетании с различными иммуномодулирующими цитокинами (IL-12, IL-15) или с геном, кодирующим иммуномодулирующий цитокин или его часть. Tat, Nef, Rev, Gag и иммуномодулирующие цитокины вводят или в виде смеси рекомбинантных белков, пептидов, или составных белков (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) или в виде плазмидной ДНК.Отчет о международном поиске был опубликован 1999.07.22.
EA200000596A 1997-12-01 1998-11-30 Tat вич-1 или его производные для профилактической и лечебной вакцинации EA004330B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000743A IT1297090B1 (it) 1997-12-01 1997-12-01 Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
PCT/EP1998/007721 WO1999027958A2 (en) 1997-12-01 1998-11-30 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination

Publications (2)

Publication Number Publication Date
EA200000596A1 true EA200000596A1 (ru) 2000-12-25
EA004330B1 EA004330B1 (ru) 2004-04-29

Family

ID=11405378

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000596A EA004330B1 (ru) 1997-12-01 1998-11-30 Tat вич-1 или его производные для профилактической и лечебной вакцинации

Country Status (23)

Country Link
US (2) US7744896B1 (ru)
EP (2) EP1698347A3 (ru)
JP (1) JP2001524531A (ru)
CN (1) CN1283121A (ru)
AP (1) AP2000001828A0 (ru)
AT (1) ATE374041T1 (ru)
AU (1) AU762893B2 (ru)
BR (1) BR9814725A (ru)
CA (1) CA2311647C (ru)
CU (1) CU20000126A7 (ru)
CY (1) CY1107818T1 (ru)
DE (1) DE69838486T2 (ru)
DK (1) DK1035865T3 (ru)
EA (1) EA004330B1 (ru)
ES (1) ES2293700T3 (ru)
IL (1) IL136372A0 (ru)
IT (1) IT1297090B1 (ru)
NZ (1) NZ505373A (ru)
OA (1) OA11419A (ru)
PL (1) PL341818A1 (ru)
PT (1) PT1035865E (ru)
TR (1) TR200001553T2 (ru)
WO (1) WO1999027958A2 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
US20010008627A1 (en) * 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
AU4082300A (en) * 1999-06-21 2001-01-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hiv tat peptides and multiple peptide conjugate system
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
AU2002358181A1 (en) * 2001-12-11 2003-07-09 Aventis Pasteur Mutated hiv tat
FR2834717B1 (fr) * 2002-01-11 2004-12-10 Bio Merieux Mutants de la proteine tat du virus vih-1
UA82998C2 (ru) 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
WO2004028561A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 免疫応答誘導方法
EP1570051B1 (en) * 2002-11-19 2009-10-28 The Trustees of The University of Pennsylvania Genetic constructs and compositions comprising rre and cte and uses thereof
AU2003292136A1 (en) * 2002-11-26 2004-06-18 Eurocine Ab Vaccines against viruses with cationic substances as adjuvants
EP1575601B1 (en) 2002-12-16 2015-07-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant vaccine viruses expressing il-15 and methods of using the same
GB0323840D0 (en) * 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP1888105A2 (en) 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
AU2007284656A1 (en) 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
GB0802224D0 (en) * 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
US9439922B2 (en) * 2008-05-14 2016-09-13 Jawaharlal Nehru Centre For Advanced Scientific Research Tat DNA sequences, gene constructs, vaccine and processes thereof
EP2411043B1 (en) 2009-03-23 2013-07-31 PIN Pharma, Inc. Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CN102153657A (zh) * 2011-01-18 2011-08-17 陕西师范大学 IL-24-Tat PTD融合蛋白及其构建方法和应用
GB201301119D0 (en) * 2013-01-22 2013-03-06 Vaxxit Srl Viral vaccines
WO2014151771A1 (en) * 2013-03-14 2014-09-25 The J. David Gladstone Institutes Compositions and methods for treating an immunodeficiency virus infection
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽
CN103936863B (zh) * 2014-04-23 2017-01-04 西安交通大学 一种调控stat3磷酸化的融合肽及其应用
CN104001155B (zh) * 2014-06-12 2016-04-13 中山大学 一种Tat蛋白及其制备方法和应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2018217897A1 (en) * 2017-05-23 2018-11-29 David Weiner Compositions and method for inducing an immune response
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83682B (en) * 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
US6107062A (en) 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
WO1994015634A1 (en) 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
WO1995031999A1 (en) * 1994-05-23 1995-11-30 Immunogiology Research Institute, Inc. Compositions of transactivating proteins of human immunodeficiency virus
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
BR0107972A (pt) * 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano

Also Published As

Publication number Publication date
PT1035865E (pt) 2007-12-07
CA2311647A1 (en) 1999-06-10
DE69838486T2 (de) 2008-06-26
AU2412699A (en) 1999-06-16
ES2293700T3 (es) 2008-03-16
AU762893B2 (en) 2003-07-10
JP2001524531A (ja) 2001-12-04
CY1107818T1 (el) 2013-06-19
IT1297090B1 (it) 1999-08-03
AP2000001828A0 (en) 2000-06-30
WO1999027958A2 (en) 1999-06-10
WO1999027958A3 (en) 1999-07-22
ITRM970743A1 (it) 1999-06-01
IL136372A0 (en) 2001-06-14
EP1698347A2 (en) 2006-09-06
CN1283121A (zh) 2001-02-07
NZ505373A (en) 2003-07-25
CA2311647C (en) 2013-03-19
CU20000126A7 (es) 2005-10-19
ATE374041T1 (de) 2007-10-15
OA11419A (en) 2004-04-21
US8197820B2 (en) 2012-06-12
EP1698347A3 (en) 2006-12-20
BR9814725A (pt) 2000-10-03
EP1035865B1 (en) 2007-09-26
US20100015087A1 (en) 2010-01-21
EA004330B1 (ru) 2004-04-29
PL341818A1 (en) 2001-05-07
TR200001553T2 (tr) 2000-11-21
WO1999027958A9 (en) 1999-09-10
DE69838486D1 (de) 2007-11-08
EP1035865A2 (en) 2000-09-20
US7744896B1 (en) 2010-06-29
DK1035865T3 (da) 2008-02-04

Similar Documents

Publication Publication Date Title
EA200000596A1 (ru) Tat вич-1 или его производные для профилактической и лечебной вакцинации
ES2307496T3 (es) Composiciones de vacuna, antigenos y peptidos.
US7612168B2 (en) Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
CA2224257A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
RU98101904A (ru) Рекомбинантный вирус mva и его использование
MXPA00006263A (es) Inmunogenos anti-retrovirales, su preparacion y su uso.
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
SE9903031D0 (sv) Peptide mixture and vaccine against a chronic viral infection
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
KR950005326A (ko) 재조합 아데노바이러스 백신
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
ATE119166T1 (de) An hiv relatierte peptide.
CA2325345A1 (en) Medicaments for inducing cytotoxic t-cells
CA2209135A1 (en) Human immunodeficiency virus vaccines and therapeutics containing replication-impaired hiv-1 nef-deletion mutants
CA2339850A1 (en) A non-cytolytic recombinant hiv-1 vaccine
WO1992000098A1 (en) Methods of inducing immune response to aids virus
WO2007004231A1 (en) Hiv-1 vaccinogens with immunomodulators
OA08716A (fr) Peptides susceptibles d'être reconnus par des anticorps induits contre des retrovirus d'immunodéficience humaine (virus HIV), leurs applications au diagnostic des infections dues à certains de ces virus et, le cas échéant, à la vaccination contre le sida.
WO2003082908A2 (en) Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein
RU93005036A (ru) Способ лечения вируса иммунодефицита человека

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU